Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome c pseudogene 44 (CYCSP44, also called HCP44) is one of 49 identified human pseudogenes derived from the functional cytochrome c gene (CYCS/HCS). Pseudogenes like CYCSP44 result from retrotransposition events; they lack introns, are often truncated, usually contain disabling mutations, and do not produce functional products. Comprehensive genomic and transcriptomic analyses have shown that these cytochrome c pseudogenes, including HCP44/CYCSP44, are not expressed, are not involved in electron transport or apoptosis, and have no known role in human biology or disease. As such, CYCSP44 is neither a therapeutic target nor a functional gene, and its annotation is primarily of interest for understanding gene evolution and genome structure[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome c pseudogene 44 (CYCSP44).